Delivery Order SPE2DP16D0008-0042
Award Date
9/8/17
Potential Completion Date
9/10/18
Potential Value
$89K
Federal Agency
Medical Supply Chain
Awardee
Genentech Usa, Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
South San Francisco, CA 94080, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Genentech USA, Inc., a foreign-owned, for-profit manufacturer of pharmaceuticals and biologics. The contract is for the supply of oseltamivir phosphate, an antiviral medication, with a total ceiling value of $259,393.47. The contract is a firm-fixed price delivery order with a completion date of September 20, 2017. Genentech is the prime contractor, and no major subcontractors were identified. The contract is...
This is a $112,687.80 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Genentech USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer, for the supply of oseltamivir phosphate, an antiviral medication. The contract is not designated as a set-aside. Genentech holds several key contract vehicles with federal agencies, including a $4.9 billion Federal Supply Schedule with the Department of Veterans Affairs for pharmaceutical products, and a...
This is a delivery order (SPE2DP16D0008|0041) awarded by the Medical Supply Chain division of the Defense Logistics Agency (DLA) to Genentech USA, Inc., a foreign-owned, for-profit manufacturer of pharmaceuticals. The $9,862,682.40 firm-fixed-price contract is for the delivery of oseltamivir phosphate, an antiviral medication, to support the federal government's medical supply needs. The contract does not have a set-aside designation. Genentech holds several key contract vehicles with federal...
This is a delivery order under a Federal Supply Schedule contract awarded by the Defense Logistics Agency (DLA) to Genentech USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer. The contract is for the delivery of oseltamivir phosphate, an antiviral medication, with a ceiling value of $8,434,278.00 and a period of performance ending on September 20, 2017. The contract does not have a set-aside designation. Genentech holds several key contract vehicles with federal agencies,...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Genentech USA, Inc., a biotechnology company and manufacturer of pharmaceuticals. The contract is for the delivery of oseltamivir phosphate, an antiviral medication, with a ceiling value of $6,993,124.11. The contract is a firm fixed price delivery order type, with a completion date of September 20, 2017. This contract award was made under a larger indefinite delivery contract vehicle between Genentech and the...
This is a federal delivery order awarded by the Defense Logistics Agency (DLA) to Genentech USA, Inc., a foreign-owned, for-profit biotechnology company. The $93,573.18 firm-fixed-price contract is for the delivery of oseltamivir phosphate, an antiviral medication. The award falls under a larger indefinite delivery contract between Genentech and DLA valued at $27.9 million to supply medical supplies and critical pharmaceuticals for the Department of Defense. No set-aside designation was used....
This is a firm fixed-price delivery order contract awarded by the Medical Supply Chain, a component of the Department of Defense, to Genentech USA, Inc. The contract has a ceiling value of $353,101.26 and is for the delivery of oseltamivir phosphate, an antiviral medication. The contract was awarded under a larger federal supply schedule contract between Genentech and the Department of Veterans Affairs, valued at $4.9 billion, that enables the company to efficiently provide pharmaceuticals and...
This is a Delivery Order (SPE2DP19F5699) awarded by the Medical Supply Chain, a component of the Defense Logistics Agency (DLA), to Genentech USA, Inc. for the supply of oseltamivir phosphate, an antiviral medication, at a Firm Fixed Price of $95,996.16. The contract has an ultimate completion date of September 3, 2020. Genentech is a foreign-owned, for-profit manufacturer of pharmaceuticals and biologics that holds several contract vehicles with federal agencies, including a $4.9 billion...
This is a federal contract award from the Medical Supply Chain of the Department of Defense to Genentech USA, Inc., a foreign-owned, for-profit manufacturer of pharmaceuticals and biologics. The contract is for the delivery of oseltamivir phosphate, an antiviral medication, with a ceiling value of $149,340.18. The contract is a firm-fixed price delivery order placed under an existing vehicle, with an ultimate completion date of September 21, 2017. No set-aside designation was used. Genentech...
This federal contract award, SPE2DP18D0011|SPE2DP18F6016, was issued by the Defense Logistics Agency (DLA) to Genentech USA, Inc., a foreign-owned, for-profit biotechnology and pharmaceutical manufacturer. The contract, valued at $115,959.93, is for the delivery of oseltamivir phosphate, a critical antiviral medication. The contract is a firm fixed-price Delivery Order, with a completion date of August 3, 2023. Genentech USA, Inc. has previously received several significant federal contract...